Sometimes restraint is the wiser choice — half of patients are cured with PD-1 alone.
New Treatments and Therapies
Here, we delve into the dynamic world of cutting-edge cancer treatments and therapies. Stay informed about groundbreaking advancements in cancer care, from emerging therapies to novel treatment modalities. Discover how science and technology are shaping the future of oncology, offering new hope and possibilities to those affected by cancer. Join us as we explore innovative approaches that hold the promise of brighter tomorrows for patients and their families.
Five groundbreaking trials from the ASCO Plenary are transforming cancer care—ushering in biomarker-led immunotherapy across multiple disease types.
On December 20, 2024, the FDA granted accelerated approval for a groundbreaking new treatment approach for patients with metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation. The newly approved regimen combines encorafenib (Braftovi) with cetuximab and mFOLFOX6 (a chemotherapy regimen consisting of fluorouracil, leucovorin, and oxaliplatin). This marks a pivotal step forward in the …
Cutaneous squamous cell carcinoma (CSCC) is one of the most common skin cancers, with cases ranging from easily treatable localized lesions to aggressive forms that can metastasize or become life-threatening. On December 13, 2024, the FDA approved cosibelimab-ipdl (Unloxcyt), a PD-L1 blocking antibody, offering new hope for adults with metastatic CSCC (mCSCC) or locally advanced …
On December 4, 2024, the FDA approved durvalumab (Imfinzi) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. This approval offers a new standard of care for LS-SCLC, providing patients with improved survival outcomes in a traditionally challenging disease. Key Findings from the ADRIATIC Trial The FDA …
On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri), marking a significant milestone in cancer care. This is the first approved systemic therapy targeting NRG1 gene fusions, a rare but actionable driver mutation in certain cancers. Zenocutuzumab-zbco is approved for adults with: This approval offers a new, precision-medicine option for patients with …
On November 20, 2024, the FDA granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for the treatment of previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC). This decision brings new hope for patients battling this aggressive and hard-to-treat disease, offering a targeted option for a population with limited therapeutic choices. The …
Bladder cancer, particularly muscle-invasive bladder cancer (MIBC), poses significant treatment challenges due to its high recurrence rate and aggressive nature. Traditionally, neoadjuvant chemotherapy followed by surgery (radical cystectomy) has been the standard of care for cisplatin-eligible patients. However, researchers have been exploring ways to improve outcomes by incorporating immunotherapy into treatment. A recent phase 3 …
On October 18, 2024, the U.S. Food and Drug Administration (FDA) approved zolbetuximab-clzb (Vyloy, Astellas Pharma), a novel treatment for adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This approval brings a much-needed new option for patients whose tumors express the CLDN18.2 protein, as identified through an FDA-approved test. …
Hope for Advanced Bladder Cancer Bladder cancer is often like an unwelcome party crasher, popping up when least expected and causing considerable distress. Yet, in the realm of oncology, we are constantly seeking new ways to send such unwelcome guests packing. Today, I am thrilled to share some exciting news about a promising new approach …